IceCure Medical Ltd. (ICCM)

IceCure Medical Ltd. surged as positive clinical milestone news fueled bullish sentiment, and stocks have been trading up by 235.21 percent. Key Takeaways Nearly 90% recurrence‑free outcomes in small kidney tumors spotlight ProSense as a serious minimally invasive player.

IceCure Medical Ltd. stocks have been trading up by 86.42 percent amid strong optimism over its latest cancer treatment advances. Key Takeaways New ECIO 2026 data showed nearly 90% recurrence-free outcomes for small kidney tumors treated with ProSense, spotlighting a key clinical win.

The balance sheet shows about $8.90M in cash against roughly $4.84M in liabilities and positive working capital of about $7.78M even before the new $5.5M raise. For traders, ICCM is a classic high-risk, high-reward setup where sentiment and news flow drive the tape more than current earnings.

IceCure reported a 70% increase in its active U.S. commercial install base of ProSense systems.

FDA authorization, updated breast-surgeon guidance and more physician demand lifted ProSense leads and procedures in major U.S. cities.